Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 17 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

13%

2 of 16 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

17Total
P 1 (16)
P 3 (1)

Trial Status

Completed16
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT07374224Phase 1RecruitingPrimary

A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet

NCT05437094Phase 1CompletedPrimary

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

NCT06126861Phase 1CompletedPrimary

The Mass Balance Study of LP-168 in Healthy Subjects

NCT02276274Phase 3CompletedPrimary

Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects

NCT01473108Phase 1CompletedPrimary

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

NCT04511611Phase 1CompletedPrimary

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects

NCT04511637Phase 1CompletedPrimary

Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects

NCT04366622Phase 1CompletedPrimary

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

NCT04364464Phase 1CompletedPrimary

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

NCT03424135Phase 1CompletedPrimary

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

NCT03517930Phase 1CompletedPrimary

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects

NCT03517943Phase 1CompletedPrimary

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects

NCT02629562Phase 1CompletedPrimary

Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects

NCT03136666Phase 1CompletedPrimary

Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.

NCT03074058Phase 1CompletedPrimary

Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet

NCT02286518Phase 1CompletedPrimary

TAK-114 Single- and Multiple-Dose Phase 1 Study

NCT02113020Phase 1CompletedPrimary

A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

Showing all 17 trials

Research Network

Activity Timeline